Ben Creagh-Brown: How Should HI-PEITHO Influence the Management of Intermediate-Risk Pulmonary Embolism?
Ben Creagh-Brown, Consultant Physician at Royal Surrey County Hospital NHS Foundation Trust, shared a post on LinkedIn about a recent article by Kenneth Rosenfield et al. published in NEJM, adding:
“As an intensivist with a background in respiratory medicine, who works at a major cancer centre – I’m very interested in risk stratification and treatment for higher-risk pulmonary embolism (PE).
Thanks to my colleagues in interventional radiology we have access to 24/7 catheter-directed thrombolysis (CDT) for appropriate patients (mainly major PE with contraindication to systemic thrombolysis).
The HI-PEITHO trial was published in this week’s NEJM:
- P (Population): 544 stable adults with acute, intermediate-risk PE showing signs of cardiorespiratory distress. (RV/LV ratio ≥1, elevated troponin)
- I (Intervention): ultrasound-facilitated, catheter-directed fibrinolysis: US-CDF (alteplase (8.8mg unilateral / about 16.9mg bilateral) via EkoSonic system) and anticoagulation.
- C (Comparison): Anticoagulation alone.
- O (Outcomes)
Efficacy: US-CDF cut the 7-day composite risk of PE-related death, collapse, or recurrence by 61% (4.0% vs. 10.3%, P=0.005).
Safety: No statistical difference in 7-day major bleeding (4.1% vs. 2.2%) and 0% intracranial haemorrhage in both groups.
This potentially expands the possible uses of CDT to a broader group of patients.
The real question is – to what extent was the ultrasound really facilitating?
Does the application of thrombolysis via an appropriately placed catheter improve outcomes even if it’s not an EKOS catheter? I guess so, but IDK. What are your thoughts?”
Title: Ultrasound-Facilitated, Catheter-Directed Fibrinolysis for Acute Pulmonary Embolism
Authors: Kenneth Rosenfield, Frederikus A. Klok, Gregory Piazza, Andrew S.P. Sharp, Fionnuala Ní Áinle, Michael R. Jaff, Stefano Barco, Samuel Z. Goldhaber, Nils Kucher, Irene M. Lang, Irene Schmidtmann, Keith M. Sterling, Aleksander Araszkiewicz, Vishal Arora, Rafael Cires-Drouet, John Coghlan, Lukas Hobohm, Wulf D. Ito, Kurt Jacobson, Christoph Kaiser, Grzegorz Kopec, Kristin Marx, Samuel McElwee, Nicolas Meneveau, Peter Monteleone, Jose M. Montero-Cabezas, Christoph B. Olivier, John Park, Marek Roik, Rahul Sakhuja, Andi Tego, Markus Theurl, Gautam Visveswaran, Jan Albert Vos, Michael N. Young, Federico M. Asch, Stavros V. Konstantinides

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026